drugset / Trial / NCT05188417

A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke

NCT05188417

Phase 2 Unknown 266 enrolled GrandPharma (China) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is a prospective, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tirofiban in combination with intravenous thrombolytic therapy with alteplase in acute ischemic stroke

Timeline

Start
2021-12-09
Primary completion
2023-03-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirofiban Other / unclassified 0.1 ug/kg Intravenous

Indications